Study of Transrectal ultrasound combined with contrast-enhanced ultrasound in the diagnosis of low rectal cancer

Study of Transrectal endoluminal ultrasound combined with contrast-enhanced ultrasound in the diagnosis of low rectal adenocarcinoma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000036249

Enrollment

Unknown

Registered

2020-08-22

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

low rectal adenocarcinoma

Interventions

Gold Standard:Take histopathology as the gold standard TNM (Tumor Node Metastasis, TNM) staging standards are based on the 7th edition of the "AJCC Tumor Staging Manual" formulated by the American Joi

Index test:Transrectal&#32

endoluminal&#32

ultrasound&#32

combined&#32

with&#32

contrast-enhanced&#32

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: All patients were diagnosed as rectal cancer by colonoscopy and postoperative pathological biopsy; the tumor was within 2 cm from the dentate line, or the lower edge of the tumor was within 5 cm from the anal edge; none received chemotherapy before the operation; the rectal ultrasound showed the tumor before the operation The anal sphincter was not invaded and no distant metastasis was seen on MRI; the anus control function was normal before surgery.

Exclusion criteria

Exclusion criteria: Insufficiency of major organs such as the heart, liver and kidney; surgery cannot be performed due to severe involvement of surrounding tissues or organs; previous history of anal surgery; accompanied by serious infectious diseases of the digestive tract, severe allergies, blood coagulation disorders, and specific infections, etc. You cannot participate in this study.

Design outcomes

Primary

Measure	Time frame
Preoperative T staging of low rectal cancer by transrectal ultrasound;Histopathological T staging;Intravascular ultrasound is performed for tumors located in the mucosal cavity with ultrasound staging as T1 stage, and the time of arrival of contrast agent (AT), time to peak (TTP), peak intensity (PI) and other indicators are analyzed.;Carry out intravascular ultrasound contrast examination for benign mass adenoma, internal hemorrhoids, inflammation, granuloma, etc. and normal rectal wall of the mucosal layer, and analyze the arrival time (AT), time to peak (TTP) and peak intensity (PI) of the contrast agent.;Intracavitary ultrasound T stage T1-T4 patients with low rectal cancer underwent intravascular ultrasound contrast examination to analyze the contrast agent arrival time (AT), time to peak (TTP), and peak intensity (PI);SEN, SPE, ACC, AUC of ROC;	—

Measure

Time frame

Preoperative T staging of low rectal cancer by transrectal ultrasound;Histopathological T staging;Intravascular ultrasound is performed for tumors located in the mucosal cavity with ultrasound staging as T1 stage, and the time of arrival of contrast agent (AT), time to peak (TTP), peak intensity (PI) and other indicators are analyzed.;Carry out intravascular ultrasound contrast examination for benign mass adenoma, internal hemorrhoids, inflammation, granuloma, etc. and normal rectal wall of the mucosal layer, and analyze the arrival time (AT), time to peak (TTP) and peak intensity (PI) of the contrast agent.;Intracavitary ultrasound T stage T1-T4 patients with low rectal cancer underwent intravascular ultrasound contrast examination to analyze the contrast agent arrival time (AT), time to peak (TTP), and peak intensity (PI);SEN, SPE, ACC, AUC of ROC;

—

Countries

China

Contacts

Public ContactHao-Qiang Yin

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

silverival@aliyun.com+86 18917763362

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026